METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New radiation drug targets tough prostate cancer in early trial
Disease control Recruiting nowThis early study tests a new drug (3D1015) that delivers radiation directly to prostate cancer cells in men with advanced, treatment-resistant prostate cancer. The main goals are to see if it is safe, how the body handles it, and what dose works best. Only 8 men will take part in…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Chunjing Yu • Aim: Disease control
Last updated May 26, 2026 07:01 UTC
-
New hope for advanced prostate cancer: first human trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called INR731, alone or with standard hormone therapy, in adults with metastatic prostate cancer that no longer responds to hormone treatment. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Ab…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 06:50 UTC
-
New hope for tough prostate cancer: experimental drug opevesostat faces off against standard treatments
Disease control Recruiting nowThis study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard drugs (abiraterone or enzalutamide) in about 1,300 men with metastatic castration-resistant prostate cancer that worsened after one prior hormone treatment. The goal is to see i…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 06:50 UTC
-
New hope for tough cancers: experimental drug targets resistant tumors
Disease control Recruiting nowThis early-stage study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 26, 2026 06:50 UTC
-
New drug combo targets tough prostate cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called KTX2001, alone or with another drug (darolutamide), in men with advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check safety, find the best dose, and see if it helps control the can…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 06:45 UTC
-
Could gut bacteria help fight resistant prostate cancer?
Disease control Recruiting nowThis study tests whether adding a combination of antibiotics to the standard drug enzalutamide can safely improve treatment for men with metastatic castration-resistant prostate cancer (mCRPC). About 39 participants will receive two weeks of amoxicillin and metronidazole, then tw…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated May 26, 2026 06:44 UTC
-
New drug trial targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase study tests a new drug called xaluritamig in 40 adults with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The main goal is to check the drug's safety and side effects. Researchers will also measure how the drug moves …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
Could green tea boost chemo for tough prostate cancer?
Disease control Recruiting nowThis study tests whether adding green tea and quercetin (natural supplements) to standard chemotherapy (docetaxel) helps men with advanced prostate cancer that no longer responds to hormone therapy. About 99 participants will receive either the supplements or a placebo alongside …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Charles Drew University of Medicine and Science • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New study explores kidney impact on prostate cancer drug safety
Disease control Recruiting nowThis study is for men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It tests how a radioactive drug (lutetium (177Lu) vipivotide tetraxetan) behaves in the body and its safety, especially in those with moderate or severe kidney…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Extended immunotherapy shows promise for tough prostate cancer
Disease control Recruiting nowThis early-phase study tests whether giving an extended course of Sipuleucel-T (an immunotherapy) can strengthen the immune system's attack on prostate cancer cells in men with metastatic castration-resistant prostate cancer. About 13 participants will receive three infusions ove…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New cancer pill shows promise in early trial for tough tumors
Disease control Recruiting nowThis early-stage study tests an experimental drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The drug works by boosting the immune system to fight tumors. The main goals are to check safety and find the right dose, with a later …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called XL092, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their gro…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated May 19, 2026 11:46 UTC
-
New drug combo aims to shrink tough prostate tumors
Disease control Recruiting nowThis study tests a new drug, REGN5678, alone or with another drug (cemiplimab) in people with advanced prostate cancer that no longer responds to hormone therapy. The goal is to find safe doses and see if the drugs can shrink tumors by helping the immune system attack cancer cell…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 19, 2026 11:46 UTC
-
New hope for tough prostate cancer: experimental drug AB-3028 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called AB-3028 in about 190 men whose prostate cancer has spread and stopped responding to standard hormone treatments. The main goal is to find a safe dose and see if the drug can shrink tumors or slow the disease. Participants must have a s…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Arsenal Biosciences, Inc. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC